Crux Biomedical

About Crux Biomedical

Crux Biomedical, Inc. was a medical device company established in 2004, specializing in the development of minimally invasive vascular devices. The company was founded by the renowned cardiovascular surgeon and prolific inventor, Dr. Thomas Fogarty, alongside Dr. Frank Arko, who was the Chief of Endovascular Surgery at the University of Texas Southwestern. Dr. Fogarty is a distinguished figure in medicine, credited with over 190 medical patents, including the industry-standard Fogarty balloon embolectomy catheter, and has founded or co-founded over 45 medical technology companies. His extensive experience in identifying and solving clinical needs directly shaped Crux's mission.

The firm focused on addressing the prevention of pulmonary embolisms (PE), a life-threatening condition where blood clots block lung arteries. Crux Biomedical's core product was the Crux VCF System, an inferior vena cava (IVC) filter. This implantable device was engineered to capture blood clots before they could travel to the lungs. The key differentiator of the Crux filter was its novel design, which departed from traditional conical shapes. This design facilitated bi-directional retrieval, meaning it could be implanted and, importantly, later removed through either the femoral vein in the leg or the jugular vein in the neck, which was a significant improvement over existing filters that often posed retrieval challenges. The device was also designed for better self-centering within the vena cava, aiming to reduce complications like migration or perforation and improve retrieval success rates. The target market consisted of clinicians and hospitals treating patients at high risk for PE, including those undergoing complex surgeries, trauma patients, or individuals with deep vein thrombosis.

The company achieved significant milestones, including securing CE Mark approval in Europe in late 2011 and FDA 510(k) clearance in the United States in July 2012. Its pivotal clinical trials demonstrated a high retrieval success rate of 98%. After successfully developing its technology and gaining regulatory approvals, Crux Biomedical was acquired by Volcano Corporation in December 2012 for $36 million in cash, with potential for additional milestone payments. This acquisition integrated Crux's therapeutic device into Volcano's portfolio of diagnostic and intravascular imaging products, aiming to provide a comprehensive solution for vascular medicine.